Actuate Therapeutics, Inc. (ACTU) stock
ACTUNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.25−0.02 (-6.12%)
Close on Nov 17, 2026Market cap $6.04MP/E –Yield –
Actuate Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Actuate Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $8.57M, down 27.6% year over year. For fiscal 2025 it was $10.29M, down 44.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.29M | -44.9% |
| FY2024 | Dec 31, 2024 | $18.68M | -14.0% |
| FY2023 | Dec 31, 2023 | $21.71M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.81M | -16.8% |
| Q2 FY2026 | Jun 30, 2026 | $2.07M | -25.2% |
| Q1 FY2026 | Mar 31, 2026 | $2.57M | -20.3% |
| Q4 FY2025 | Dec 31, 2025 | $2.13M | -42.2% |
| Q3 FY2025 | Sep 30, 2025 | $2.18M | -42.0% |
| Q2 FY2025 | Jun 30, 2025 | $2.76M | -36.8% |
| Q1 FY2025 | Mar 31, 2025 | $3.22M | -53.1% |
| Q4 FY2024 | Dec 31, 2024 | $3.69M | -44.5% |
| Q3 FY2024 | Sep 30, 2024 | $3.76M | -34.8% |
| Q2 FY2024 | Jun 30, 2024 | $4.37M | -8.5% |
| Q1 FY2024 | Mar 31, 2024 | $6.86M | – |
| Q4 FY2023 | Dec 31, 2023 | $6.65M | – |
| Q3 FY2023 | Sep 30, 2023 | $5.76M | – |
| Q2 FY2023 | Jun 30, 2023 | $4.78M | – |
See a number that looks wrong?